ACT Stock Overview
Develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
AlzChem Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €59.40 |
| 52 Week High | €61.00 |
| 52 Week Low | €22.30 |
| Beta | 0.95 |
| 11 Month Change | -1.98% |
| 3 Month Change | 15.56% |
| 1 Year Change | 160.53% |
| 33 Year Change | 154.94% |
| 5 Year Change | 170.00% |
| Change since IPO | 120.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACT | DE Chemicals | DE Market | |
|---|---|---|---|
| 7D | 10.4% | -1.6% | -0.5% |
| 1Y | 160.5% | -1.0% | 8.3% |
Return vs Industry: ACT exceeded the German Chemicals industry which returned -1% over the past year.
Return vs Market: ACT exceeded the German Market which returned 8.3% over the past year.
Price Volatility
| ACT volatility | |
|---|---|
| ACT Average Weekly Movement | 7.4% |
| Chemicals Industry Average Movement | 4.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ACT's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: ACT's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1908 | 1,607 | Andreas Niedermaier | www.alzchem.com |
AlzChem Group AG, together with its subsidiaries, develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The company offers dietary supplements under the Creapure and Alipure brands; preparation of guanidinoacetic acid as a nutritional feed additives under the Creamino brand; creatine dietary supplements under the LIVADUR brand; products for pharmaceuticals under the Bioselect brand; curing agents, including accelerators for use in adhesives, powder coatings, printed circuit boards, and composites under the DYHARD name; and silicon nitride for ceramics, and electronics and solar applications under the SILZOT brand.
AlzChem Group AG Fundamentals Summary
| ACT fundamental statistics | |
|---|---|
| Market cap | €582.09m |
| Earnings (TTM) | €50.10m |
| Revenue (TTM) | €563.55m |
11.6x
P/E Ratio1.0x
P/S RatioIs ACT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACT income statement (TTM) | |
|---|---|
| Revenue | €563.55m |
| Cost of Revenue | €214.74m |
| Gross Profit | €348.81m |
| Other Expenses | €298.71m |
| Earnings | €50.10m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 28, 2025
| Earnings per share (EPS) | 4.92 |
| Gross Margin | 61.90% |
| Net Profit Margin | 8.89% |
| Debt/Equity Ratio | 0% |
How did ACT perform over the long term?
See historical performance and comparison